Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Queensland Health
Merck
Federal Trade Commission
Harvard Business School
Boehringer Ingelheim
UBS
Baxter
Chubb

Generated: June 21, 2018

DrugPatentWatch Database Preview

ATELVIA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Atelvia, and when can generic versions of Atelvia launch?

Atelvia is a drug marketed by Apil and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-six patent family members in thirty-one countries.

The generic ingredient in ATELVIA is risedronate sodium. There are nineteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the risedronate sodium profile page.
Drug patent expirations by year for ATELVIA
Pharmacology for ATELVIA
Ingredient-typeDiphosphonates
Drug ClassBisphosphonate
Medical Subject Heading (MeSH) Categories for ATELVIA
Synonyms for ATELVIA
(1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid
(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid
(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid; sodium
(1-hydroxy-2-(3-pyridinyl)ethylidene)-bis(phosphonic acid) monosodium salt
(1-Hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid
(1-hydroxy-2-(pyridin-3-yl)ethane-1,1-diyl)bis(phosphonic acid)
(1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid)
(1-oxidanyl-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid
[1-hydroxy-1-phosphono-2-(3-pyridinyl)ethyl]phosphonic acid
[1-hydroxy-1-phosphono-2-(3-pyridyl)ethyl]phosphonic acid
[1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid
[1-Hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic Acid Monosodium Salt
1-hydroxy-1-[hydroxy(sodiooxy)phosphoryl]-2-(pyridin-3-yl)ethylphosphonic acid
1-hydroxy-2-(3-pyridinyl) ethylidene bis-phosphonic acid monosodium salt
1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE BIS-PHOSPHONIC ACID
1-Hydroxy-2-(3-pyridyl)-ethan-1,1-bis-phosphonic acid
105462-24-6
105462-24-6 (Parent)
115436-72-1
115436-72-1 (mono-hydrochloride salt)
122458-82-6
2-(3-Pyridinyl)-2-hydroxyethylidene-1,1-bisphosphonate
2-(3-pyridyl)-1-hydroxyethane-1,1-bisphosphonic acid
2689AH
436R721
462R246
934544-85-1
A801245
AB0013898
AB01274790-01
AB01275490_02
AB01275490-01
AB09807
AB2000101
AB2000344
AC-1295
AC-20120
AC-732
AC1L1JX6
AC1N5G27
AC1O3LR2
AC1Q1VB7
Acide risedroniqe
Acide risedronique
Acide risedronique [INN-French]
Acido risedronico
Acido risedronico [INN-Spanish]
Acidum risedronicum
Acidum risedronicum [INN-Latin]
Acrel
ACT03362
Actonel
Actonel (TN)
Actonel 150
AK163014
AK163015
AKOS015833432
AKOS015892564
AKOS024462575
AKOS030228065
AN-15054
AN-15580
API0004080
AS-13309
AS-13584
AX8017640
BB_SC-1157
BC206977
BDBM12576
Benet
BIDD:GT0010
Bisphosphonate 1
C08233
C7H10NNaO7P2
C7H10NO7P2.Na
C7H11NO7P2
C7H11NO7P2.H2O
CCG-213235
CHEBI:8868
CHEBI:8869
CHEMBL1654
CHEMBL923
CPD000469279
CS-1964
CS0033
CTK8F0842
D00942
D08484
D0I7IC
D0PA5S
DB00884
DRFDPXKCEWYIAW-UHFFFAOYSA-M
DTXSID2023563
FT-0631078
FT-0642593
GTPL3176
H864
HE004268
HE292529
HE298537
HMS2090C21
HSDB 7326
HY-B0148
Hydrogen [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonate (Na+)
I02-0324
I04-0049
I802
IIDJRNMFWXDHID-UHFFFAOYSA-N
J10129
JMC515594 Compound 64
K-1095
KM2Z91756Z
KS-00000XMN
KS-00000YSA
LS-106650
LS-171967
M-1366
M2289
MFCD00867080
MFCD01706268
MolPort-044-724-030
Monosodium (1-hydroxy-2-(3-pyridinyl)ethylidene)bisphosphonate
Monosodium 1-Hydroxy-2-(3-pyridyl)ethylidene-1,1-diphosphonate
Monosodium Risedronate
Monosodium Risedronate Hemipentahydrate
NCGC00346521-01
NE 58019
NE 58095
NE-58095
OFG5EXG60L
Optinate
Optinate Septimum
P,P'-[1-Hydroxy-2-(3-pyridonyl)ethylidene]bis-phosphonic acid sodium salt
Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-
Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-, disodium salt
Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-, monosodium salt
Phosphonic acid, (2-hydroxy-2-(3-pyridinyl)ethylidene)bis-, disodium salt
Phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis-
PubChem14002
Q-201723
RESEDRONIC ACID
Ridron
Ridron (TN)
RIS
Risdronate
RISEDREMATE SODIUM
Risedronate
Risedronate (sodium)
RISEDRONATE NA
Risedronate sodium
Risedronate sodium (USP)
Risedronate sodium [USAN:USP]
Risedronate sodium [USAN]
risedronate sodium anhydrous
Risedronate sodium hydrate
Risedronate sodium monohydrate
Risedronate sodium salt
Risedronic acid
Risedronic acid (Actonel)
Risedronic acid (INN)
Risedronic acid [INN:BAN]
Risedronic acid monohydrate
Risedronic acid monosodium salt
RISEDRONIC ACID SODIUM
Risedronic acid sodium salt
risedronic acid, monosodium salt
RISEDRONIC ACID, SODIUM SALT
Risedronsaure
RTC-070962
s1428
s1874
SAM001246537
SC-14176
SCHEMBL18377
SCHEMBL18378
SCHEMBL2115050
sodium hydrogen (1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl)phosphonate
sodium hydrogen(1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl)phosphonate
sodium hydroxy-(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphinate
sodium hydroxy-[1-hydroxy-1-phosphono-2-(3-pyridyl)ethyl]phosphinate
SODIUM HYDROXY-1-HYDROXY-1-PHOSPHONO-2-(PYRIDIN-3-YL)ETHYLPHOSPHINATE
Sodium risedronate
sodium risedronate hydrate
Sodium trihydrogen (1-hydroxy-2-(3-pyridyl)ethylidene)diphosphonate
TC-070962
UNII-KM2Z91756Z
UNII-OFG5EXG60L
Z2684418685
ZINC1531009

US Patents and Regulatory Information for ATELVIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apil ATELVIA risedronate sodium TABLET, DELAYED RELEASE;ORAL 022560-001 Oct 8, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Apil ATELVIA risedronate sodium TABLET, DELAYED RELEASE;ORAL 022560-001 Oct 8, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Apil ATELVIA risedronate sodium TABLET, DELAYED RELEASE;ORAL 022560-001 Oct 8, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for ATELVIA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil ATELVIA risedronate sodium TABLET, DELAYED RELEASE;ORAL 022560-001 Oct 8, 2010 ➤ Sign Up ➤ Sign Up
Apil ATELVIA risedronate sodium TABLET, DELAYED RELEASE;ORAL 022560-001 Oct 8, 2010 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ATELVIA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Delayed-release Tablets 35 mg ➤ Subscribe 2011-07-19

Non-Orange Book US Patents for ATELVIA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,409,614 Low dosage forms of risedronate or its salts ➤ Sign Up
8,535,718 Dosage forms of bisphosphonates ➤ Sign Up
8,409,615 Low dosage forms of risedronate or its salts ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
McKesson
Argus Health
UBS
Covington
Healthtrust
McKinsey
Accenture
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.